1. Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy
- Author
-
Vitello, A, Grova, M, Pugliese, D, Rizzello, F, Lanzarotto, F, Lavagna, A, Caccaro, R, Cappello, M, Viola, A, Ribaldone, Dg, Principi, M, Stasi, E, Scribano, Ml, Maida, M, Soriano, A, Bezzio, C, Bodini, G, Mocciaro, F, Privitera, Ac, Simondi, D, Giuffrida, E, D'Incà, R, Ricci, C, Gionchetti, P, Armuzzi, A, Orlando, A, Daperno, M, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD, Vitello A., Grova M., Pugliese D., Rizzello F., Lanzarotto F., Lavagna A., Caccaro R., Cappello M., Viola A., Ribaldone D.G., Principi M., Stasi E., Scribano M.L., Maida M., Soriano A., Bezzio C., Bodini G., Mocciaro F., Privitera A.C., Simondi D., Giuffrida E., D'Inca R., Ricci C., Gionchetti P., Armuzzi A., Orlando A., and Daperno M.
- Subjects
musculoskeletal diseases ,Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Effectiveness ,Young Adult ,Internal medicine ,Adalimumab ,Medicine ,Humans ,Adverse effect ,skin and connective tissue diseases ,Colectomy ,Aged ,Retrospective Studies ,Real-world evidence ,Hepatology ,business.industry ,Gastroenterology ,Effectivene ,Retrospective cohort study ,Induction Chemotherapy ,Middle Aged ,medicine.disease ,Ulcerative colitis ,Discontinuation ,Clinical Practice ,Treatment Outcome ,Italy ,Safety ,Concomitant ,Colitis, Ulcerative ,Female ,Tumor Necrosis Factor Inhibitors ,business ,medicine.drug - Abstract
Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.0%). At week 8, clinical responses were observed in 177 cases (46.5%) and clinical remission in 136 cases (35.7%). At 12 months, remission was observed in 128 cases (33.6%). Overall, 44 patients required colectomy, and 170 patients (44.6%) were still taking adalimumab when data were collected. Variables associated with adalimumab discontinuation were concomitant steroid treatment, severe clinical-endoscopic activity at baseline, need for adalimumab intensification and drug-related adverse events. Variables associated with colectomy were concomitant steroid treatment and high baseline C-reactive protein. Conclusion Adalimumab is safe and effective for the treatment of ulcerative colitis.
- Published
- 2021